Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 1

Status

Completed 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 4Thoracic 3Breast 3Gynecologic 2Other solid neoplasm 1Lymphoid 1CNS 1

Conditions

Neoplasms 3Neoplasm Metastasis 1

Interventions

pembrolizumab 62Paclitaxel 51Gemcitabine 50Carboplatin 45Docetaxel 43Cisplatin 31Pemetrexed 30Nivolumab 28Bevacizumab 28atezolizumab 22Fluorouracil 22Cetuximab 21Capecitabine 21Irinotecan 20Leucovorin 19Afatinib 18Erlotinib Hydrochloride 15trametinib 14Trastuzumab 13Ipilimumab 13130-nm albumin-bound paclitaxel 13regorafenib 11olaparib 11Sorafenib 11Oxaliplatin 11Drug Therapy 11eribulin 10enzalutamide 10Midazolam 10Injections 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × XL147 × Tumor-Agnostic × Clear all
NCT01587040 2022-04-19

Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen

Sanofi

Phase 1/2 Completed
61 enrolled 13 charts
Tumor-Agnostic

Neoplasms

NCT01943838 2016-04-22

A Study of the Safety and Pharmacokinetics of SAR245408 Tablets in Patients With Solid Tumors or Lymphoma

Sanofi

Phase 1 Completed
18 enrolled
Tumor-Agnostic

Neoplasms

NCT01357330 2016-04-01

Oral SAR245408 (XL147) and Oral MSC1936369B in Patients With Locally Advanced or Metastatic Solid Tumors

Sanofi

Phase 1 Completed
18 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT01392924 2014-12-03

Safety and Pharmacokinetics of SAR245408 Daily Oral in Patients With Solid Tumors

Sanofi

Phase 1 Completed
10 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡